## KAJARIA CERAMICS LIMITED

<u>Disclosure pursuant to the provisions of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 - For the financial year 2024-25</u>

The Kajaria Employee Stock Option Scheme 2015 ('ESOP Scheme 2015') was approved by the shareholders of the Company on September 7, 2015. During the year 2021-22, the ESOP Scheme 2015 was modified by the Board of Directors, as recommended by the Nomination and Remuneration Committee of the Company, to make the same align pursuant to the provisions of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The shareholders of the Company have, through postal ballot on March 24, 2022, approved addition of 5,25,000 options and accordingly, the total options under the ESOP Scheme 2015 increased, which is equivalent to 15,87,000 equity shares of Re. 1 each.

- **A.** Relevant disclosures in terms of the Accounting Standards (Ind-AS) 102 'Share based Payment' has been made in Note No. 43 of the Notes of the Standalone Financial Statements, forming part of the Annual Report for the financial year 2024-25 of the Company.
- **B.** Diluted Earnings Per Share ('EPS') pursuant to the issue of shares on exercise of options calculated in accordance with Indian Accounting Standards (Ind-AS) 33 'Earnings Per Share' is Rs. 12.81.

## C. Details related to ESOP Scheme 2015:

1.	Description of the ESOP Scheme 2015 is summarised below:				
Sr. No.	Particulars	Details			
a)	Date of shareholders' approval	<ul> <li>September 7, 2015</li> <li>March 24, 2022 (Options increased by 5,25,000 Options)</li> </ul>			
b)	Total number of options approved	As on March 31, 2025, the details of the options granted under the ESOP Scheme 2015 are as under:  Tranche 1:  5,31,000 equity shares of Rs. 2/- each were approved by the shareholders of the Company and out of which, 2,29,000 equity shares of Rs. 2/- each were granted at an exercise price of Rs. 850/- per share.  Subsequent to the sub-division, the face value of equity shares is Re. 1/- each and the approved equity shares have been increased to 10,62,000 equity shares of Re. 1/- each and total quantum of options granted in Tranche 1 has also been increased to 4,58,000 equity shares of Re. 1/- each and an exercise price has, accordingly, been reduced to Rs. 425/- per share.  Tranche 2:  7,05,200 equity shares of Re. 1 each were granted at			

		an exercise price of Rs. 980 per share.					
		Tranche 3:					
		1,32,400 equity shares of Re. 1 each were granted at an exercise price of Rs. 980 per share.					
c)	Vesting requirements	<ul> <li>Options granted will vest over a period of 5 (five) years as per the schedule below:</li> <li>0% of options shall vest at the end of a period of 1 (one) year from the grant date.</li> <li>10% of options shall vest at the end of a period of 2 (two) year from the grant date.</li> <li>20% of options shall vest at the end of a period of 3 (three) year from the grant date.</li> <li>30% of options shall vest at the end of a period of 4 (four) year from the grant date.</li> <li>40% of options shall vest at the end of a period of 5 (five) year from the grant date.</li> <li>1st Tranche (Grant) was made on October 20, 2015 and exercise period was completed on October 19, 2023.</li> <li>2nd Tranche (Grant) was made on March 2, 2022.</li> </ul>					
1		o 3 <sup>rd</sup> Tranche (Grant) was made on April 19, 2022.					
d)	Exercise price	Tranche 1:  Subsequent to the sub-division, the face value of equity shares is Re. 1/- each and an exercise price has, accordingly, been reduced to Rs. 425/- per share from Rs. 850/- per share.					
		Tranches 2 & 3:					
		Rs. 980/- per share					
e)	Maximum term of options granted	8 (Eight) years from the grant date					
f)	Source of shares (primary, secondary or combination)	Primary					
g)	Variation in terms of options	Not Applicable					
2.	Method used to account for ESO	P Scheme 2015 - Intrinsic or fair value:					
	The compensation cost of stock op value method.	otions granted to employees is calculated based on Fair					

3.	Where the company opts for expensing of the options using the intrinsic value of the options, Difference between the employee compensation cost so computed and the employee compensation cost that shall have been recognized if it had used the fair value of the options shall be disclosed. The impact of this difference on profits and on EPS of the Company shall also be disclosed: Not Applicable						
4.	Movement of options during the financial year 2024-25 are as follows:						
	Particulars		Details				
a)	Number of option the beginning of the		t 7,51,100				
b)	Number of option the year	s granted during	0				
c)	Number of options during the year	s forfeited/lapsed	55,690				
d)	Number of optior the year	ns vested during	ng 1,35,000				
e)	Number of options exercised during the Year 13,990						
f)	Number of share result of exercise		13,990				
g)	options (INR),	d by exercise of , if scheme is directly by the					
h)	Loan repaid by the year from received						
i)	Number of option the end of the number of optio exercisable at the	year (excluding ns exercised 8					
j)	Number of option the end of the yea		1,83,530				
5.	Weighted-average exercise prices and weighted-average fair values of opti whose exercise price equals or exceeds or is less than the market price of the sto						
	Grant date		October 20, 2015 (Tranche 1)				
	Vesting	October 20,	October 20,	October 20,	October 20,		
	date	2017	2018	2019	2020	-	
	Fair Value of option at grant date	260.22	310.20	354.01	392.99		

	(Rs.) Exercise	425.0	0	425.	.00	42	5.00	4	425.00	)	
	Price (Rs.)	)									
	Grant date			March 2, 2022 (Tranche 2)							
	Vesting date			March 2, 2024		· ·		-		ch 2, )27	
	Fair Value of option at grant date (Rs.)		40	404.29 429		9.57 444.28		.28	460.59		
	Exercise Price (Rs.)		98	980.00 980.00 98		980	980.00		0.00	]	
	Grant date			April 19, 2022 (Tranche 3)					1		
	Vesting date			April 19, April 19, 2024 2025		il 19,	), April 19,		April 19, 2027		
		Fair Value of option		9.13		3.45	2026 447.54		462.58		1
	at grant date Exercise Pri		98	0.00	980	0.00	980	.00	980	0.00	
6.	Employee wise	dotaile of	ontio	no grant	od dur	ing the	financia	lvoor	2024	25	dor
	ESOP Scheme 2		optio								
Sr. No.	Particulars			Name		Design	Designation N		umber of Exercis		cise ice
INO.				Employee					options Pri granted		ICE
									ing the		
								year			
a)	Senior Manageria						Nil				
b)	Any other empreceives a grant			Nil							
	year of option a										
	5% or more of op	otion grante	ed								
	during that year						<b>A</b> 1'1				
c)	Identified employers were granted or	oyees wh					Nil				
	any one year,		_								
	exceeding 1% o										
	capital (excluding										
	warrants and cor	,									
	the company at grant	tne time	OT								
	grant										
7.	Description of the method and significant assumptions used during the year estimate the fair value of options including the following information:						r to				
Sr. No.	Particulars			Tranche	e 1	Tranche 2 Tranche			nche 3		
a)	Weighted-average share price	e value	of Rs. 918.10 Rs. 1038.60 R		Rs. 1031.25		5				
	Exercise Price			Rs. 42	25	R	Rs. 980		Rs. 980		
			,	After sub-							
				of face va							
			sn	ares to R F.Y. 2010		'					
	l		ı	201	,	1					

	Expected volatility	27.63%	32.21% - 33.41%	32.59% - 33.95%			
	Expected option life	2.5 - 5.5 years	5 - 6.5 years	5 - 6.5 years			
	Expected dividend yield	0.40% p.a.	0.76% p.a.	0.83% p.a.			
	Risk-free interest rate	7.15% - 7.30% p.a.	5.94%-6.30% p.a.	6.41%-6.68% p.a.			
	Model used	Black Scholes Merton Option Pricing Model					
b)	Method used and the assumptions made to incorporate the effects of expected early exercise	, o					
c)	How expected volatility was determined, including an explanation of the extent to which expected volatility was based on historical volatility	The volatility is estimated from the actual movement in share prices of the Company over one year preceding the grant date. This historical volatility is the annualised standard deviation of the continuously compounded rates of daily stock returns.					
d)	Whether and how any other features of the option grant were incorporated into the measurement of fair value, such as a market condition	adopted.					
8.	Until all options granted in have lapsed, disclosures of options: Not Applicable						

D. Details related to ESPS - Not Applicable

E. Details related to SAR - Not Applicable

F. Details related to GEBS/RBS - Not Applicable

G. Details related to Trust - Not Applicable